AD109 Reduces Apnea-Hypopnea Index in PAP-Intolerant OSA Patients

Obstructive sleep apnea (OSA) contributes to significant morbidity, including cardiovascular disease, yet its management is frequently complicated by poor adherence to continuous positive airway pressure (CPAP) therapy, the standard of care [1, 2, 3, 4]. This common intolerance or refusal of CPAP creates a substantial unmet need for alternative treatments that address the underlying pathophysiology of the condition [5, 6]. Consequently, research has shifted toward pharmacological interventions targeting specific mechanisms like upper airway neuromuscular dysfunction, aiming to provide more tolerable options [2, 7]. A recent study now provides efficacy and safety data on an investigational oral pharmacotherapy for this challenging patient population.